IQANOVA ATLAS™
Continuously Updated QSP–SBML Intelligence
From open mechanistic blueprints to validated combination-therapy decision engines
Academia
Pharma
Biotech
Clinical Strategy
Update cadence: 3–6 months | Format: Subscription
Why QSP Models Fail to Scale
Rapid Evolution
Literature and clinical evidence evolve faster than models can keep pace
Static Assets
Most QSP assets are static, bespoke, and undocumented
Late-Stage Failures
Combination therapies and safety drive costly late-stage failures
Regulatory Demands
Regulators require traceability, validation, and version control

Result: QSP models are under-used in real decision-making.
The Solution
Introducing
IQANOVA ATLAS™
A living database of QSP models, encoded in SBML, continuously upgraded using new literature, new clinical studies, and structured validation workflows.
Not software.
Not consulting.
Decision-grade mechanistic intelligence as a subscription
Explore ATLAS Models
What ATLAS Contains
Each ATLAS Model is built to deliver decision-grade intelligence with complete transparency and traceability.
1
SBML-Encoded Structure
Mechanistic structure encoded in standardized SBML format for interoperability
2
Parameter Governance
Rigorous parameter governance where applicable, ensuring reliability
3
Clinical Endpoint Mapping
Direct mapping to clinical endpoints for practical application
4
Versioning & Provenance
Complete versioning and provenance tracking for regulatory compliance
5
Intended Context of Use
Clear ICU documentation defining appropriate model applications
AI-assisted internally, human-approved externally
Free vs Paid: Clear Boundary
🟢 FREE — ATLAS Open
  • Unparameterised SBML
  • Compartments, species, reactions
  • Conceptual annotations
  • Annual static snapshot
  • Academic citation required
Purpose:
  • Transparency
  • Education
  • Community adoption
🔒 PAID — Decision-Grade Layers
  • Parameterised SBML
  • Fitted & validated SBML
  • Combination therapy & ADE models
  • Quarterly or semi-annual updates
ATLAS Product Architecture
Four integrated layers delivering progressively sophisticated intelligence
ATLAS Open
Unparameterised SBML (Free)
ATLAS Curated
Parameterised, literature-aligned SBML
ATLAS Clinical
Fitted, validated, regulator-ready QSP
ATLAS Combo
Combination therapy & adverse drug effects
Subscription Tiers
Flexible subscription options designed for different audiences and use cases
Annual Subscription Pricing
€0
ATLAS Open
Free access to unparameterised models
€5K
Curated Academic
Per model / year
€30K
Curated Industry
Per model / year
€120K
Clinical
Per programme / year
€180K–€250K
Combo & Safety
Per year
High-Margin Extensions
Optional add-ons that deliver additional value and revenue opportunities
Custom Calibration
€25k–€75k
Tailored parameter fitting for specific datasets
Data Ingestion
€30k+
Sponsor-specific data integration and processing
Regulatory Briefing
€20k
Comprehensive regulatory documentation packages
On-Prem Deployment
€40k–€80k
VPC or on-premises installation and support
Training Workshops
€10k
Hands-on training for research teams
Why 3 vs 6 Months Matters
Currency = Credibility
6-Month Updates
Academic Tier
  • Key publications
  • Meta-analyses
  • Parameter refinements
Balanced approach for foundational research needs
3-Month Updates
Industry / Clinical
  • New trials & follow-ups
  • Safety signals
  • Dose/regimen changes
  • Subgroup analyses
Rapid response to evolving clinical landscape
IQANOVA ATLAS v1 Launch Set
Our flagship portfolio covers critical therapeutic areas with 5–7 validated models
Immuno-Oncology
  • NSCLC IO Platform
  • CAR-T / T-cell Therapy
  • IO Combination Therapy
Neurodegeneration
  • Alzheimer's Biomarker Progression
  • Parkinson's / α-Synuclein
Metabolism / Physiology
  • GLP-1 Metabolic Regulation
  • Thermophysiology / Bioenergetics
Why This Scales
ATLAS is built on a business model designed for sustainable growth and market leadership
Recurring Revenue
Subscription model ensures predictable, growing revenue streams
Low Churn
Models become embedded in workflows, creating high switching costs
Clear Upsell Path
Natural progression from Open to Curated to Clinical tiers
Regulator-Friendly
Positioning aligns with regulatory requirements and expectations
AI Leverage
AI acceleration without regulatory risk through human validation
Positioning Statement
IQANOVA ATLAS™
Continuously updated, regulator-aware QSP models — from open mechanistic blueprints to validated combination-therapy decision engines.
Investor Snapshot
Revenue Example (Conservative)
Demonstrating clear path to €1.8M ARR with fewer than 20 customers
10
Industry Clients
Curated tier (2 models each)
5
Clinical Programmes
Full validation and support
3
Combo Licences
Advanced therapy models
€1.8M
Total ARR
With <20 customers
Next Steps
Launch ATLAS Open
Build visibility and community adoption
Convert Early Adopters
Transition users to Curated tier
Secure Clinical Subscriptions
Target 3–5 clinical programmes
Expand Catalogue
Grow Combo & Safety offerings